SC
BIO icon

Solstein Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Solstein Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16
Closed -$3.86K – 456
2025
Q2 		$3.86K Hold
16
– – ﹤0.01% 413
2025
Q1 		$3.9K Hold
16
– – ﹤0.01% 284
2024
Q4 		$5.26K Hold
16
– – ﹤0.01% 271
2024
Q3 		$5.35K Hold
16
– – ﹤0.01% 272
2024
Q2 		$4.37K Hold
16
– – ﹤0.01% 279
2024
Q1 		$5.53K Hold
16
– – ﹤0.01% 264
2023
Q4 		$5.17K Hold
16
– – ﹤0.01% 262
2023
Q3 		$5.74K Hold
16
– – ﹤0.01% 252
2023
Q2 		$6.07K Hold
16
– – 0.01% 249
2023
Q1 		$7.66K Hold
16
– – 0.01% 215
2022
Q4 		$6.73K Hold
16
– – 0.01% 227
2022
Q3 		$7K Hold
16
– – 0.01% 243
2022
Q2 		$8K Hold
16
– – 0.01% 268
2022
Q1 		$9K Hold
16
– – 0.01% 296
2021
Q4 		$12K Hold
16
– – 0.01% 311
2021
Q3 		$12K Hold
16
– – 0.01% 338
2021
Q2 		$10K Hold
16
– – 0.01% 331
2021
Q1 		$9K Buy
+16
New +$9.47K 0.01% 300

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Solstein Capital's BIO Position: Q3 2025 in Review

Solstein Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 16 shares — an estimated $3.86K sold.

Solstein Capital first reported a position in BIO in Q1 2021 and held it in 18 quarters. The position peaked at $12K in Q4 2021. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Solstein Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
  • Solstein Capital sold 16 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $3.86K.
  • Solstein Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 18 quarters.
  • Solstein Capital's Bio-Rad Laboratories Class A position peaked at $12K in Q4 2021.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Solstein Capital's 13F filing for Q3 2025, filed 12 Nov 2025.